Integrated Diagnostic for Heart Failure

NCT01798797 — Completed, 100 participants, Medtronic

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT01798797
StatusCompleted
Study typeObservational
Enrollment100 (Actual)
SponsorMedtronic (Industry)
ConditionsHeart Failure
Datesstart 2013-08-01, primary completion 2015-07-01, completion 2015-07-01, first posted 2013-02-26, last updated 2018-09-25
Locations3 sites in Canada

Related Papers Related Patents Related Grants Related Experts
All trials for Heart Failure

-Summary

A prospective post-market study to evaluate the performance and clinic usability of heart failure risk status (HFRS) feature on CareLink.

Expand all sections  ·  Collapse all

+Detailed description

Patients with systolic heart failure (HF) implanted with Medtronic wireless implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy device with defibrillation capabilities (CRT-D) devices will be enrolled in the study. The purpose of the study is to evaluate the usability of CareLink HFRS to manage a patient's heart failure.

+Arms and interventions

ArmTypeInterventionsDescription
no treatmentnon-randomized, all subjects who have been implanted with an ICD or CRT-D for at least 3 months

+Outcome measures

Primary outcomes

  • Heart Failure Risk Status Performance Characterization [from baseline until a subject completes 8 months of follow up]: The clinical signs and symptoms of worsening HF that are associated with an Heart Failure Risk Status triggered by an OptiVol alert

Secondary outcomes

  • Heart Failure Risk Status and medical management [from baseline for each subject until they complete 8 months of follow up]: The correlation between HFRS burden and clinician's assessment of a subject risk and the subject's medical management

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patient is 18 years of age or older
* Patient ( or patient's legally authorized representative) is willing and able to provide written informed consent
* Patient is willing and able to comply with the required study follow up visits
* Patient is implanted with a Medtronic wireless ICD or CRT-D device capable of OptiVol fluid monitoring feature
* Patient is on Medtronic CareLink network or is willing to be enrolled on the CareLink network
* Patient is being managed, or has been managed, by a HF clinician
* Patient has signed an informed consent for CareLink Network Services
* Patient is implanted with device for at least three months
* Patient is willing and able to transmit data using the CareLink home monitor (2490C).

Exclusion Criteria:

* Patient is participating in another study that may interfere with TRIAGE-HF protocol required procedures
* Patient with an implantable cardiac device that is indicated to reach ERI in less than 12 months

+Locations (3)

FacilityCityCountryStatus
Vancouver General HospitalVancouver, British ColumbiaCanada
St. Boniface HospitalWinnipeg, ManitobaCanada
Southlake Regional Health CentreNewmarket, OntarioCanada

+Investigators

  • Sean Virani, MD, Principal investigator, Vancouver General Hospital, Vancouver, British Columbia, Canada